Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV

A novel injectable pre-exposure prophylaxis, cabotegravir, has greater efficacy and acceptability than oral tenofovir/emtricitabine for prevention of HIV infection. Cabotegravir is currently priced at $22 200 per year, >185 times higher than the $60–$119 estimated cost-effectiveness threshold for...

Descripción completa

Detalles Bibliográficos
Autores principales: Pepperrell, Toby, Cross, Samuel, Hill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830540/
https://www.ncbi.nlm.nih.gov/pubmed/36632416
http://dx.doi.org/10.1093/ofid/ofac673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830540/
https://www.ncbi.nlm.nih.gov/pubmed/36632416
http://dx.doi.org/10.1093/ofid/ofac673

Ejemplares similares